NCT01142401

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Version 4 to 5 · National Cancer Institute (NCI)

Patch inspector

Version 4 to 5

171 operations 8 path groups ctgov_internal_history

Severity is deterministic uncalibrated triage metadata, not validated review priority. Operation-level severity is inferred from deterministic path rules. Rule matches shown per operation are approximate previews (they skip the pipeline's suppression passes); the authoritative classification is the stored event record.

Plain-language summary

Manual review pending.

Rules fired

arms_or_interventions_changecontact_admin_changedesign_info_changeeligibility_criteria_changeprimary_outcome_any_changesecondary_outcome_any_change

Value signals

[
  {
    "path": "/protocolSection/statusModule/startDateStruct/date",
    "signal": "timeline_earlier_adjustment",
    "category": "timeline_minor_adjustment",
    "new_type": null,
    "old_type": null,
    "severity": "low",
    "direction": "earlier",
    "new_value": "2010-05",
    "old_value": "2010-06",
    "delta_days": 31,
    "date_struct": "startDateStruct",
    "new_precision": "month",
    "old_precision": "month"
  },
  {
    "path": "/protocolSection/statusModule/primaryCompletionDateStruct/date",
    "signal": "timeline_major_slip",
    "category": "timeline_major_slip",
    "new_type": "ESTIMATED",
    "old_type": "ESTIMATED",
    "severity": "medium",
    "direction": "later",
    "new_value": "2014-06",
    "old_value": "2012-01",
    "delta_days": 882,
    "date_struct": "primaryCompletionDateStruct",
    "new_precision": "month",
    "old_precision": "month"
  }
]

Provenance

Source: ctgov_internal_history
Fetched: 2026-06-18 19:13:08+00
Raw hash: 583825ea7bda8cec3240e8f7b2190f65959dc9f17d9aa1a63cd681fb0363f7c6
Payload: Source URL

Primary outcomes Outcome measures that define the trial's primary evidence target. Triage: Critical 3 ops

replace /protocolSection/outcomesModule/primaryOutcomes/0/measure

Triage: Critical

Primary Outcome Change Operation 47

Matched rules

primary_outcome_any_change Any add/remove/replace under primary outcome measures is critical review priority.

Before

Clinical benefit rate in patients for at least 24 weeks

After

PFS

replace /protocolSection/outcomesModule/primaryOutcomes/0/timeFrame

Triage: Critical

Primary Outcome Change Operation 48

Matched rules

primary_outcome_any_change Any add/remove/replace under primary outcome measures is critical review priority.

Before

1.7 years for enrollment plus 1 year of follow-up

After

From first treatment day until objective or disease progression or death from any cause, assessed up to 4 years

add /protocolSection/outcomesModule/primaryOutcomes/0/description

Triage: Critical

Primary Outcome Change Operation 49

Matched rules

primary_outcome_any_change Any add/remove/replace under primary outcome measures is critical review priority.

After

The PFS distributions of the two treatment arms will be estimated by Kaplan-Meier.
PFS distributions will be compared by an unstratified log-rank test.

Design Trial model, phase, allocation, masking, arms, or interventions. Triage: High 19 ops

replace /protocolSection/designModule/designInfo/maskingInfo/masking

Triage: High

Design Change Operation 28

Matched rules

design_info_change Design information changes can alter allocation, masking, model, or purpose and need review.

Before

NONE

After

DOUBLE

add /protocolSection/designModule/designInfo/maskingInfo/whoMasked

Triage: High

Design Change Operation 29

Matched rules

design_info_change Design information changes can alter allocation, masking, model, or purpose and need review.

After

[
  "PARTICIPANT",
  "INVESTIGATOR"
]

replace /protocolSection/armsInterventionsModule/armGroups/0/label

Triage: High

Arm Intervention Change Operation 30

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

Before

Arm I

After

Arm I (fulvestrant)

replace /protocolSection/armsInterventionsModule/armGroups/0/type

Triage: High

Arm Intervention Change Operation 31

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

Before

ACTIVE_COMPARATOR

After

EXPERIMENTAL

add /protocolSection/armsInterventionsModule/armGroups/0/interventionNames/1

Triage: High

Arm Intervention Change Operation 32

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

After

Other: laboratory biomarker analysis

replace /protocolSection/armsInterventionsModule/armGroups/1/label

Triage: High

Arm Intervention Change Operation 33

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

Before

Arm II

After

Arm II (fulvestrant, bortezomib)

add /protocolSection/armsInterventionsModule/armGroups/1/interventionNames/0

Triage: High

Arm Intervention Change Operation 34

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

After

Drug: fulvestrant

replace /protocolSection/armsInterventionsModule/armGroups/1/interventionNames/2

Triage: High

Arm Intervention Change Operation 35

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

Before

Drug: fulvestrant

After

Other: laboratory biomarker analysis

replace /protocolSection/armsInterventionsModule/interventions/0/name

Triage: High

Arm Intervention Change Operation 36

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

Before

bortezomib

After

fulvestrant

replace /protocolSection/armsInterventionsModule/interventions/0/description

Triage: High

Arm Intervention Change Operation 37

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

Before

Given IV

After

Given intramuscularly

replace /protocolSection/armsInterventionsModule/interventions/0/armGroupLabels/0

Triage: High

Arm Intervention Change Operation 38

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

Before

Arm II

After

Arm I (fulvestrant)

add /protocolSection/armsInterventionsModule/interventions/0/armGroupLabels/1

Triage: High

Arm Intervention Change Operation 39

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

After

Arm II (fulvestrant, bortezomib)

add /protocolSection/armsInterventionsModule/interventions/0/otherNames

Triage: High

Arm Intervention Change Operation 40

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

After

[
  "Faslodex",
  "ICI 182,780"
]

replace /protocolSection/armsInterventionsModule/interventions/1/name

Triage: High

Arm Intervention Change Operation 41

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

Before

fulvestrant

After

bortezomib

replace /protocolSection/armsInterventionsModule/interventions/1/description

Triage: High

Arm Intervention Change Operation 42

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

Before

Given intramuscularly

After

Given IV

replace /protocolSection/armsInterventionsModule/interventions/1/armGroupLabels/0

Triage: High

Arm Intervention Change Operation 43

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

Before

Arm I

After

Arm II (fulvestrant, bortezomib)

remove /protocolSection/armsInterventionsModule/interventions/1/armGroupLabels/1

Triage: High

Arm Intervention Change Operation 44

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

Before

Arm II

add /protocolSection/armsInterventionsModule/interventions/1/otherNames

Triage: High

Arm Intervention Change Operation 45

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

After

[
  "LDP 341",
  "MLN341",
  "VELCADE"
]

add /protocolSection/armsInterventionsModule/interventions/2

Triage: High

Arm Intervention Change Operation 46

Matched rules

arms_or_interventions_change Arms or interventions changes can alter treatment/comparator structure.

After

{
  "name": "laboratory biomarker analysis",
  "type": "OTHER",
  "description": "Correlative studies",
  "armGroupLabels": [
    "Arm I (fulvestrant)",
    "Arm II (fulvestrant, bortezomib)"
  ]
}

Eligibility Criteria and population definition changes. Triage: High 1 ops

replace /protocolSection/eligibilityModule/eligibilityCriteria

Triage: High

Eligibility Change Operation 60

Matched rules

eligibility_criteria_change Eligibility criteria changes can alter the studied population.

Before

<p>DISEASE CHARACTERISTICS:</p><ul><li><p>Histologically or cytologically confirmed breast cancer</p><ul><li>Stage IV disease or inoperable locally advanced disease</li><li><p>Disease resistant to aromatase inhibitor (AI) (i.e., anastrazole, letrozole, or exemestane) in the adjuvant setting, and&#x2F;or disease progression after 1 or more AIs for metastatic disease</p><ul><li>Prior exposure to ≥ 1 AI regimen allowed</li><li>Prior tamoxifen allowed but not required</li></ul></li></ul></li><li>Measurable or non-measurable disease, or both</li><li>Estrogen receptor-positive disease</li><li>No known brain metastases</li><li><p>No rapidly progressive life-threatening metastases, including any of the following:</p><ul><li>Extensive hepatic involvement (&gt; 50% of the liver)</li><li>Symptomatic lymphangitic metastases</li><li>Brain or leptomeningeal involvement</li></ul></li></ul><p>PATIENT CHARACTERISTICS:</p><ul><li><p>Postmenopausal, meeting 1 of the following:</p><ul><li>At least 12 months without spontaneous menstrual bleeding</li><li>Prior bilateral salpingo-oophorectomy with or without hysterectomy</li><li>Age ≥ 55 years with a prior hysterectomy with or without oophorectomy</li><li>Age &lt; 55 years with a prior hysterectomy without oophorectomy or unknown status with a documented follicle-stimulating hormone level in postmenopausal range within the past 4 weeks</li><li>Undergoing treatment with a gonadotropin releasing hormone analog (GnRH) to suppress ovarian function (e.g., goserelin 3.6 mg every 4 weeks)</li></ul></li><li>ECOG performance status (PS) 0-2 (Karnofsky PS 60-100%)</li><li>Life expectancy &gt; 3 months</li><li>WBC ≥ 3,000&#x2F;mm^3</li><li>ANC ≥ 1,500&#x2F;mm^3</li><li>Platelet count ≥ 100,000&#x2F;mm^3</li><li>Total bilirubin normal</li><li>AST and ALT ≤ 2.5 times upper limit of normal</li><li>Creatinine normal OR creatinine clearance ≥ 60 mL&#x2F;min</li><li>More than 5 years since prior invasive malignancy except curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix</li><li>No history of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib or fulvestrant</li><li><p>No uncontrolled intercurrent illness including, but not limited to, any of the following:</p><ul><li>Ongoing or active infection</li><li>Symptomatic congestive heart failure</li><li>Unstable angina pectoris</li><li>Cardiac arrhythmia</li><li>Psychiatric illness and&#x2F;or social situations that would limit compliance with study requirements</li></ul></li><li>No peripheral neuropathy ≥ grade 2</li></ul><p>PRIOR CONCURRENT THERAPY:</p><ul><li>See Disease Characteristics</li><li>One prior chemotherapy regimen for metastatic disease allowed</li><li>Prior bevacizumab allowed</li><li><p>At least 4 weeks since up to 2 doses of prior fulvestrant</p><ul><li>The interval between the first fulvestrant dose and registration must be ≤ 6 weeks</li></ul></li><li>More than 4 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas or mitomycin C)</li><li>No prior bortezomib</li><li>No other concurrent investigational agents</li><li>No concurrent combination antiretroviral therapy for HIV-positive patients</li><li><p>No concurrent anticancer treatment except for the following:</p><ul><li>Bisphosphonates for bone metastases</li><li><p>GnRH analog allowed provided patient had progressive disease on a GnRH analog plus a selective estrogen-receptor modulator (SERM) or an AI</p><ul><li>SERM or AI must be discontinued</li></ul></li></ul></li><li>No concurrent over-the-counter remedy or herbal supplement (for patients randomized to bortezomib arm)</li><li>No other concurrent anticancer agents or therapies</li></ul>

After

<p>Inclusion Criteria:</p><ul><li>ELIGIBILITY CRITERIA FOR ARM A AND ARM B</li><li>Patients must have histologically or cytologically confirmed ER+ positive breast cancer</li><li>Patients must be postmenopausal, defined as: (1) a history of at least 12 months without spontaneous menstrual bleeding, (2) prior bilateral salpingo-oophorectomy, with or without hysterectomy, (3) age &gt;= 55 years with a prior hysterectomy with or without oophorectomy, (4) age &lt; 55 years with a prior hysterectomy without oophorectomy or unknown status, with a documented FSH level in postmenopausal range within 4 week s of registration, (5) receiving a gonadotropin releasing hormone analog (GnRH) to suppress ovarian function (eg, goserelin 3.6 mg q 4 weeks)</li><li>Patients must have stage IV disease or inoperable locally advanced disease</li><li>Patients may have measurable disease only, non-measurable disease only, or both (RECIST 1.1); it is anticipated that at least 50% of patients will have only non-measurable disease</li><li>Patients are required to have disease that is resistant to aromatase inhibitor (AI), which is defined either as relapse while receiving adjuvant A.I. therapy (ie, anastrazole, letrozole, or exemestane), and&#x2F;or disease progression after one or more A.I.s for metastatic disease; prior exposure to more than one AI is permitted</li><li>Patient may have had prior tamoxifen but are not required to</li><li>Patients may have received up to one prior chemotherapy regimen for metastatic disease</li><li>Patients may have received prior bevacizumab</li><li>Patients who have received up to 2 doses of fulvestrant given within a 4 week period prior to registration are eligible; the interval between the first fulvestrant dose and registration must be 6 weeks or less; patients may have received EITHER 250 mg or 500 mg of fulvestrant previously; if the patient has received 250 mg, they will receive the 500 mg loading dose on study day -14; if they already received 500 mg, they will begin the study on day +1</li><li>Life expectancy of greater than 3 months</li><li>ECOG performance status =&lt; 2 (Karnofsky &gt;= 60%)</li><li>Leukocytes &gt;= 3,000&#x2F;mcL</li><li>Absolute neutrophil count &gt;= 1,500&#x2F;mcL</li><li>Platelets &gt;= 100,000&#x2F;mcL</li><li>Total bilirubin within normal institutional limits</li><li>AST(SGOT)&#x2F;ALT(SGPT) =&lt; 2.5 x institutional upper limit of normal</li><li>Creatinine within normal institutional limits OR</li><li>Creatinine clearance &gt;= 60 mL&#x2F;min&#x2F;1.73
m^2 for patients with creatinine levels above institutional normal</li><li>Patients must be disease-free of prior invasive malignancies for &gt;= 5 years with the exception of: curatively-treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix</li><li>Patients must have the ability to understand and the willingness to sign a written informed consent document</li><li>The effects of bortezomib on the developing human fetus at the recommended therapeutic dose are unknown; for this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately</li><li>ELIGIBILITY CRITERIA FOR ARM C</li><li>Previously met all eligibility criteria for arms A and B and registered on trial to arm A (fulvestrant alone)</li><li>Disease progression on arm A and agreeable to crossover to arm C</li><li>Has received no intervening therapy (ie, alternative endocrine therapy, chemotherapy, biologic therapy) between disease progression on arm A and registration an arm C</li><li>ECOG performance status 0-2</li><li>Tumor measurements (eg, CT scan of chest&#x2F;abdomen&#x2F;pelvis) within 4 weeks of registration to arm C</li><li><p>Normal organ and marrow function as defined below (within 2 weeks of registration on arm C):</p><ul><li>Leukocytes &gt;= 3,000&#x2F;mcL</li><li>Absolute neutrophil count &gt;= 1,500&#x2F;mcL</li><li>Platelets &gt;= 100,000&#x2F;mcL</li><li>Total bilirubin within normal institutional limits</li><li>AST(SGOT)&#x2F;ALT(SGPT) =&lt; 2.5 x institutional upper limit of normal</li><li>Creatinine within normal institutional limits OR</li><li>Creatinine clearance &gt;= 60 mL&#x2F;min&#x2F;1.73
m^2 for patients with creatinine levels above institutional normal</li></ul></li></ul><p>Exclusion Criteria:</p><ul><li>EXCLUSION CRITERIA FOR ARM A AND ARM B</li><li>Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier</li><li>Patients may not be receiving any other investigational agents</li><li>Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events</li><li>Presence of rapidly progressive, life-threatening metastases; this includes patients with extensive hepatic involvement (&gt; 50% of the liver involved), symptomatic lymphangitic metastases, or brain or leptomeningeal involvement</li><li>History of allergic reactions attributed to compounds of similar chemical or biologic composition to bortezomib or fulvestrant</li><li>Patients who are concomitantly receiving bortezomib and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy</li><li>Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness&#x2F;social situations that would limit compliance with study requirements</li><li>HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with bortezomib; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated</li><li>Patients who have previously received fulvestrant</li><li>Patients who have previously received bortezomib</li><li>Concomitant anticancer treatment with the following exceptions: (1) bisphosphonates for bone metastases, (2) a GnRH analog is permitted if the patient had progressive disease on a GnRH analog plus a SERM or an AI; the GnRH analog may continue but the SERM or AI must be discontinued</li><li>Grade 2 or more peripheral neuropathy because the dose limiting toxicity of bortezomib is neuropathy</li></ul>

Secondary outcomes Additional endpoints and outcome descriptions. Triage: High 10 ops

replace /protocolSection/outcomesModule/secondaryOutcomes/0/measure

Triage: High

Secondary Outcome Change Operation 50

Matched rules

secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.

Before

Progression-free survival at 24 weeks

After

Clinical benefit rate (CBR) (CR, PR, or SD)

replace /protocolSection/outcomesModule/secondaryOutcomes/0/timeFrame

Triage: High

Secondary Outcome Change Operation 51

Matched rules

secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.

Before

1.7 years for enrollment plus 1 year of follow-up

After

Up to 24 weeks

add /protocolSection/outcomesModule/secondaryOutcomes/0/description

Triage: High

Secondary Outcome Change Operation 52

Matched rules

secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.

After

Ninety-five percent confidence intervals will be calculated for the clinical benefit response proportion in each arm via binomial proportions.

replace /protocolSection/outcomesModule/secondaryOutcomes/1/measure

Triage: High

Secondary Outcome Change Operation 53

Matched rules

secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.

Before

Overall survival

After

Percentage of progression-free

replace /protocolSection/outcomesModule/secondaryOutcomes/1/timeFrame

Triage: High

Secondary Outcome Change Operation 54

Matched rules

secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.

Before

1.7 years for enrollment plus 1 year of follow-up

After

Up to 24 weeks

add /protocolSection/outcomesModule/secondaryOutcomes/1/description

Triage: High

Secondary Outcome Change Operation 55

Matched rules

secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.

After

Ninety-five percent confidence intervals will be calculated for the percent progression-free at 24 weeks in each arm via binomial proportions

replace /protocolSection/outcomesModule/secondaryOutcomes/2/measure

Triage: High

Secondary Outcome Change Operation 56

Matched rules

secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.

Before

Clinical benefit rate at 12 and 24 weeks in patients who crossover from fulvestrant alone to the combination treatment

After

Overall response rate

replace /protocolSection/outcomesModule/secondaryOutcomes/2/timeFrame

Triage: High

Secondary Outcome Change Operation 57

Matched rules

secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.

Before

1.7 years for enrollment plus 1 year of follow-up

After

From first treatment day until death, assessed up to 4 years

add /protocolSection/outcomesModule/secondaryOutcomes/2/description

Triage: High

Secondary Outcome Change Operation 58

Matched rules

secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.

After

Using Kaplan-Meier method.

add /protocolSection/outcomesModule/secondaryOutcomes/3

Triage: High

Secondary Outcome Change Operation 59

Matched rules

secondary_outcome_any_change Any add/remove/replace under secondary outcome measures is high review priority.

After

{
  "measure": "Toxicity as assessed by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0",
  "timeFrame": "Up to 4 years"
}

Timeline Start, primary completion, and completion date movement. Triage: Medium 2 ops

replace /protocolSection/statusModule/startDateStruct/date

Triage: Medium

Timeline Shift Operation 9

Matched rules

start_timeline_change Start date changes are operational timeline signals.

Before

2010-06

After

2010-05

replace /protocolSection/statusModule/primaryCompletionDateStruct/date

Triage: Medium

Timeline Shift Operation 10

Matched rules

primary_completion_timeline_change Primary completion date changes are operational timeline signals.

Before

2012-01

After

2014-06

Contacts and locations Site, contact, and location updates that are usually operational. Triage: Low 111 ops

remove /protocolSection/contactsLocationsModule/centralContacts

Triage: Low

Administrative Contact Change Operation 61

Matched rules

contact_admin_change Central contact updates are usually administrative.

Before

[
  {
    "name": "Kerin Adelson, MD",
    "role": "CONTACT",
    "email": "kerin.adelson@mssm.edu",
    "phone": "212-241-2299"
  },
  {
    "name": "Joseph Sparano, MD",
    "role": "CONTACT",
    "email": "jsparano@montefiore.org",
    "phone": "718-904-2555"
  }
]

replace /protocolSection/contactsLocationsModule/overallOfficials/0/name

Triage: Uncategorized

Uncategorized Operation 62

Before

Kerin Adelson, MD

After

Kerin Adelson

replace /protocolSection/contactsLocationsModule/overallOfficials/0/affiliation

Triage: Uncategorized

Uncategorized Operation 63

Before

Tisch Cancer Institute at Mount Sinai School of Medicine

After

Montefiore Medical Center

replace /protocolSection/contactsLocationsModule/locations/0/facility

Triage: Uncategorized

Uncategorized Operation 64

Before

University of Connecticut Health Center

After

University of Connecticut

replace /protocolSection/contactsLocationsModule/locations/0/contacts/0/name

Triage: Uncategorized

Uncategorized Operation 65

Before

Susan Tannenbaum, MD

After

Susan H. Tannenbaum

replace /protocolSection/contactsLocationsModule/locations/0/contacts/0/phone

Triage: Uncategorized

Uncategorized Operation 66

Before

860-679-2474

After

800-579-7822

replace /protocolSection/contactsLocationsModule/locations/0/contacts/1/name

Triage: Uncategorized

Uncategorized Operation 67

Before

Susan Tannenbaum, MD

After

Susan H. Tannenbaum

replace /protocolSection/contactsLocationsModule/locations/1/facility

Triage: Uncategorized

Uncategorized Operation 68

Before

Maimonides Cancer Center

After

Yale University

replace /protocolSection/contactsLocationsModule/locations/1/city

Triage: Uncategorized

Uncategorized Operation 69

Before

Brooklyn

After

New Haven

replace /protocolSection/contactsLocationsModule/locations/1/state

Triage: Uncategorized

Uncategorized Operation 70

Before

New York

After

Connecticut

replace /protocolSection/contactsLocationsModule/locations/1/zip

Triage: Uncategorized

Uncategorized Operation 71

Before

After

06520-8032

replace /protocolSection/contactsLocationsModule/locations/1/contacts/0/name

Triage: Uncategorized

Uncategorized Operation 72

Before

Susan Burdette-Radoux, MD

After

Gina G. Chung

replace /protocolSection/contactsLocationsModule/locations/1/contacts/0/phone

Triage: Uncategorized

Uncategorized Operation 73

Before

718-765-2644

After

203-785-5702

replace /protocolSection/contactsLocationsModule/locations/1/contacts/0/email

Triage: Uncategorized

Uncategorized Operation 74

Before

sburdette-radoux@maimonides.org

After

gina.chung@yale.edu

replace /protocolSection/contactsLocationsModule/locations/1/contacts/1/name

Triage: Uncategorized

Uncategorized Operation 75

Before

Susan Burdette-Radoux, MD

After

Gina G. Chung